HIK — Hikma Pharmaceuticals Balance Sheet
0.000.00%
- £4.21bn
- £5.04bn
- $3.16bn
- 90
- 45
- 94
- 93
Annual balance sheet for Hikma Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 347 | 450 | 292 | 229 | 213 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 734 | 876 | 841 | 873 | 973 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 1,922 | 2,094 | 1,999 | 2,100 | 2,263 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1,068 | 1,146 | 1,081 | 1,141 | 1,326 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 4,135 | 4,372 | 4,471 | 4,680 | 5,133 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1,028 | 1,016 | 1,077 | 1,339 | 1,978 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 2,000 | 1,919 | 2,336 | 2,482 | 2,823 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 2,135 | 2,453 | 2,135 | 2,198 | 2,310 |
Total Liabilities & Shareholders' Equity | 4,135 | 4,372 | 4,471 | 4,680 | 5,133 |
Total Common Shares Outstanding |